The Cramer Conundrum: Unpacking the Rot in Thermo Fisher Scientific's Shares In a recent conversation, Jim Cramer attributed the decline in Thermo Fisher Scientific's (NYSE:TMO) stock performance to a rotation into AI investments.
However, this explanation raises more questions than answers. Thermo Fisher Scientific has seen its shares surge 8% since September 10th, but beneath this upward trend lies a complex story.
The company's CEO, Marc Casper, noted at the Morgan Stanley healthcare conference that funding for biotechnology companies improved in mid 2025 and even more so in 2026.